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Abstract
Objectives—Non-fatal overdose remains a significant source of morbidity among people who
inject drugs (IDU). Although depression and social support are important in shaping the health of
IDU, little is known about the relationship between these factors and overdose. Therefore, we
sought to determine whether depressive symptoms and social support predicted non-fatal overdose
among IDU in a Canadian setting.
Methods—Data were derived from three prospective cohorts of people who use drugs: the
Vancouver Injection Drug Users Study (VIDUS), the ACCESS Cohort, and the At-Risk Youth
Study (ARYS). Multilevel modeling was used to determine if depression and social support were
significant predictors of non-fatal overdose across time. Analyses were stratified by sex.
Results—There were 1,931 participants included in this analysis, including 653 (33.8%) females
and 69 (3.6%) youth 20 years old or younger. Depressed men (Adjusted odds ratio [AOR] =1.53,
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95% confidence intervals [CI] =1.25, 1.87) and women (Adjusted odds ratio [AOR] =2.23, 95%
confidence intervals [CI] =1.65, 3.00) were more likely to experience a non-fatal overdose.
Further, among women, those who reported having 3 or more persons they could rely upon for
social support were less likely to experience a non-fatal overdose (AOR=0.54, 95% 0.31, 0.93).
Conclusion—Although depression was a significant predictor of non-fatal drug overdose, social
support was a significant predictor among women only. Possible strategies to prevent non-fatal
overdose may include identifying IDU experiencing severe depressive symptoms and providing
targeted mental health treatments and mobilizing interpersonal social support among IDU,
especially among women.
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1. INTRODUCTION
Non-fatal overdose is an inadvertent or deliberate consumption of a dose much larger than
that either habitually used by the individual or ordinarily used for treatment of an illness,
and often results in a serious toxic reaction. Although considerably more attention has been
devoted to the study of fatal overdose, non-fatal overdose is more common and is associated
with a range of harms. For instance, non-fatal overdose remains an important determinant of
morbidity among injection drug users (IDU), and can lead to aspiration pneumonia, hypoxic
brain injury, rhabdomyolysis, and renal failure (Darke and Hall, 2003). Prevalence estimates
of IDU who have experienced non-fatal overdoses in the previous 12 months is 17% among
opiate users in Canada (Milloy et al., 2008b). Other estimates include 58.5% lifetime history
of non-fatal overdose and 8.9% non-fatal overdose in the last six months among IDU in
Vancouver (Milloy et al., 2008b). Among rural drug users in Kentucky USA, 28% report a
lifetime non-fatal overdose (Havens et al., 2011).
Previous prospective research with IDU in Vancouver, BC, identified several predictors of
non-fatal overdose, such as heroin and cocaine injection, benzodiazepine use, requiring help
injecting, binge drug use, homelessness, alcohol use, street injecting, non-injectable opiate
use, speedball use, and recent incarceration (Kerr et al., 2007a). Other observed risk factors
for non-fatal overdose include sex trade involvement (Milloy et al., 2008a). An Australian
study identified extensive polydrug use and having overdosed in the previous year as
significant predictors of non-fatal overdose (Darke et al., 2005). A study in the US found
experiencing serious withdrawal symptoms in the past two months and younger age as
significant determinants of non-fatal overdose (Coffin et al., 2007). However, more research
is required to identify specific subgroups of drug users who are at greater risk for non-fatal
overdose. For example, among rural drug users, significant risk factors associated with a
greater number of non-fatal overdoses included history of drug treatment, 30-day history of
injection of prescription opioids, meeting diagnostic criteria for post-traumatic stress
disorder (PTSD) and having more members in one’s support network (Havens et al., 2011).
Yet, the role of mental health status as a risk factor for overdose has not been thoroughly
examined (Tobin and Latkin, 2003).
Several studies have investigated the relationship between depression and drug use, with the
prevalence of depression among IDU ranging from 25% to 81% (Callaly et al., 2001,
Springer, 2012, Teesson et al., 2005, Pilowsky et al., 2011, Conner et al., 2008, Mackesy-
Amiti et al., 2012). A meta-analysis of 55 studies investigating the association between
depression and substance related behaviors among IDU identified 55% of participants with
above average levels of depressive symptoms (Conner et al., 2008).
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Prior research contends that individuals with psychiatric disorders, such as mood and
anxiety disorders, engage in drug use to self-medicate or cope with their psychiatric
disorders (Khantzian, 1985, Potvin et al., 2003). Thus depressed IDU might be more likely
to use illicit drugs to self-medicate or ease their depressive symptoms and improve their
mood (Weiss et al., 1992, Bolton et al., 2009). It has been observed that among IDU, those
who reported depressive symptoms are significantly more likely to have overdosed after
adjusting for age, gender, injection frequency, and physical impairment (Tobin and Latkin,
2003). However, the temporal relationships between depressive symptoms and drug
overdose have not been elucidated (Tobin and Latkin, 2003).
Researchers hypothesize that drug use leading to overdose may either be an accidental act or
a suicide attempt (Darke et al., 2004, Rossow and Lauritzen, 1999, Neale, 2000, Vingoe et
al., 1999). Some researchers argue that those who abuse drugs may suffer from poor self-
esteem and hopelessness that leads to a careless attitude towards one’s own life, leading to
an accidental non-fatal overdose (Rossow and Lauritzen, 1999, Neale, 2000). Another study
identified consumption of an unfamiliar substance, unexpectedly using a pure form of the
drug, such as heroin, and consuming drugs in an uncontrolled manner while under the
influence of alcohol as predictors of accidental non-fatal overdose (Pfab et al., 2006). A
recent longitudinal study identified thoughts of suicide acted as an independent predictor of
accidental overdose (Richer et al., 2012).
Furthermore, social network composition has been found to be associated with non-fatal
overdose (Latkin et al., 2004, Havens et al., 2011). For example, having a greater number of
network members who were IDU and a larger number of conflictual social ties among the
network members were associated with increased risk of overdose (Latkin et al., 2004).
Although social support is often viewed as a beneficial influence on the maintenance of
health promoting behaviors, in the context of networks involving other IDU, it is possible
that access to more friends who inject drugs may have the opposite effect, i.e., the so-called
dark side of social support (Turner, 1994). In other words, social connectedness can in some
instances serve to transmit social pressure to conform to unhealthy norms within a social
group, whether the behavior is sharing needles, or experimenting with new drugs (Cohen,
2004, Umberson et al., 2010). On the other hand, research also suggests that the amount of
available social supports generates positive psychological states that in turn buffer the
deleterious influence of stress, and strengthens the ability of the recipient to cope with
adversity (Cohen, 2004, Cohen and Lemay, 2007). According to this view, among IDUs,
social support may ameliorate the effect of depression on the risk for non-fatal overdose.
Previous research has indicated that women might be more responsive to social support than
men (Flaherty and Richman, 1989; Wilson et al., 1999; Shumaker and Hill, 1991). Men have
been socialized differently such that they receive more task-focused support during
childhood (Belle, 1989), and therefore are more likely to seek out instrumental rather than
emotional support (Kliewer et al., 1990; Carver et al., 1989; Lepore et al., 1993). For
example, instead of seeking social support from social relationships, males might be more
likely to resort to stress reducing activities to cope.
Although previous cross-sectional studies have identified correlates of non-fatal drug
overdose, investigations involving cohorts that examine the relationship between depression,
social support and non-fatal overdose are needed. Accordingly, the objectives of this study
were to determine whether depression and the level of social support were independent
determinants of non-fatal overdose among IDU participating in three cohort studies in
Vancouver, Canada. We also sought to test if those who were depressed and receiving more
social support were less likely to experience non-fatal overdose in comparison to those who
had little or no social support.
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The At Risk Youth Study (ARYS), Vancouver Injection Drug Users Study (VIDUS) and
AIDS Care Cohort to Evaluate Access to Survival Services (ACCESS) are open prospective
cohorts of drug users in Vancouver, Canada. These studies comprise a larger initiative
focused on the study of the natural history of injection drug use. Recruitment procedures for
the three studies are similar, with the primary modes of enrollment being self-referral, word
of mouth, and street outreach. Participants of all studies must have resided in the greater
Vancouver region and provided informed consent to be eligible. Each study also had
specific eligibility criteria, which have been described previously (Wood et al., 2006b).
Briefly, ARYS consists of drug-using street-involved youth; thus, eligibility criteria
included being between the age of 14 and 26 and the use of illicit drugs other than or in
addition to marijuana in the past 30 days. VIDUS is a study of HIV negative IDU in which
all participants must have injected an illicit drug in the previous month to be eligible for
inclusion. ACCESS is a cohort of HIV positive individuals, who, similar to those in ARYS,
must have recently used an illicit drug other than or in addition to marijuana. Detailed
sampling and recruitment procedures for these three cohorts have also been described
elsewhere (Tyndall et al., 2003, Strathdee et al., 1998, Wood et al., 2006a, 2004, 2008).
Only participants who were active injectors in the past six months at baseline were included
in this investigation.
At baseline and semi-annually, participants completed a lengthy interviewer-administered
questionnaire. Sociodemographic data, as well as information pertaining to drug use
patterns, risk behaviors, and health care utilization were collected. The survey for each study
consists of a uniform set of questions, which permits the aggregation and analysis of data
from all enrolled participants. Nurses collected blood samples for HIV and hepatitis C
serology, as well as HIV disease progression, and also provided basic medical care and
referrals to appropriate health care services. All individuals who completed a baseline
survey between September 2005 and May 2008 were eligible for inclusion. Participants
received $20 for each study visit. The University of British Columbia/Providence Health
Care Research Ethics Board approved all studies.
2.1. Measures
At baseline, participants were asked to identify their biological sex at birth and their current
sexual orientation. “Sexual minority status” was defined as answering affirmatively to one
of the following: gay, lesbian, bisexual, transsexual, transgendered, or other. Participants
who refused to report their sex at birth or sexual orientation were excluded from this
analysis.
The primary outcome was non-fatal overdose. Since polysubstance injection drug use is the
norm in our setting, and because we were interested in overdoses involving various
substances, we used a broad definition of non-fatal overdose. We simply asked participants,
“In the last six months, have you overdosed by accident (i.e., where you had a negative
reaction from using too much drugs)?” Participants who responded “yes” were defined as
experiencing a non-fatal overdose in all subsequent analyses. This definition was pilot tested
during questionnaire development.
Predictor variables of interest in this analysis were chosen based on previous work (Kerr et
al., 2007a). Sociodemographic information included sex, age, education, sexual orientation,
and cohort (ARYS, VIDUS, and ACCESS). Time-varying variables and exposures that were
measured at baseline and updated repeatedly during follow-up included drug use (heroin,
cocaine, speed, crystal meth, and morphine injection) within the last 6 months, alcohol
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binge, undergoing methadone treatment, needing help injecting, homelessness, relationship
status, income assistance support, incarceration in the last 6 months, and HIV status.
At each measurement, we used the Center for Epidemiologic Studies Depression Scale
(CES-D) with a standard cut-off of ≥16 to measure the level of depressive symptomatology
among participants (Radloff, 1977). Scores above 16 were indicative of severe depressive
symptoms and a probable diagnosis of depression (Radloff, 1977). To assess social support,
we asked participants “Who do you currently count on for support/friendship?” Response
options included partners, ex-partners, spouse, lovers, family members/relatives, friends/
neighbors, coworkers/classmates, health care workers, counselors/therapists, medical doctor/
health care worker, ministers, priests or rabbis, other, and no one. The number of support
sources was categorized into none, 1–2, and 3 or more.
2.2 Data analysis
Because non-fatal overdose was nested within individuals, i.e., measured twice a year yearly
for the same individuals, we used multilevel modeling analyses, also known as a random
intercepts modeling, to examine the relationship between socio-demographic, behavioral,
depression, and social support measures and likelihood of non-fatal overdose across time.
Time-varying variables (exposures collected at each time point) were tested, as between
subject effects on the likelihood of non-fatal overdose. Multilevel models are a
generalization of the linear model used in traditional regression analyses. Several authors
have shown that ignoring the hierarchical structure of a data set can lead to inferential errors
and that estimating random effect coefficients can more adequately model data structures
typically obtained in field research (Diez-Roux, 2000, Raudenbush and Bryk, 2002).
Cleaning and recoding the data were performed with Stata (Version 12.0) and Multilevel
Modeling was performed using HLM 6.04.
To investigate the potential effect of socio-demographic, behavioral, depressive symptoms,
and social support on likelihood of non-fatal overdose, we adopted a step-up approach and
conducted different sets of analyses (Raudenbush and Bryk, 2002). The initial sample
(n=2,865) was restricted to participants who were active IDU (n=2,012) with complete
socio-demographic data, resulting in a sample size of n=1,931 (1,931/2012=96.0%). A first
set of analyses included only parameters operationalizing time, to explore whether or not the
proportion of participants who experienced a non-fatal overdose changed across time (model
1). Then the main exposure, severe depressive symptoms (yes vs. no), was added to the
model (model 2). Socio-demographic variables were then added to identify significant
predictors associated with non-fatal overdose at each year (model 3). The covariates added
included sex, sexual orientation, birthplace (Canada vs. foreign-born, age (≤20 years vs. >20
years), and finished high school (yes vs. no). Time-varying covariates included,
homelessness (yes vs. no), size of social network (none, 1–2, or 3 or more), relationship
status (single vs. in a relationship), welfare (no or recipient), incarcerated in the last 6
months (yes vs. no), HIV status (negative vs. positive), had an alcoholic binge in the last 6
months (yes vs. no), and injected heroin, cocaine, speed, crystal meth, or morphine), all of
which were included as moderating variables at baseline. Next, an interaction term of
depression X social support was added to the previous models. Since the interaction term
was not significant, these results are not presented.
3. RESULTS
In total, 1,931 participants with complete socio-demographic data were used for this
analysis. Of the sample, 66.2% (1,278) were male, 63.8% (n=1,231) were born in Canada,
85.5% (n=1,650) were heterosexual, and 3.6% (n=69) were 20 years old or younger (table
1). The proportion of the sample that injected heroin, cocaine, crystal meth, morphine, and
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speed were 54.5%, 41.9%, 20.7%, 19.0%, and 15.4%, respectively. Also, the proportion of
the sample that injected both heroin and cocaine was 25.6%. Only a small percentage, 2.1%,
injected all of the five drug substances. Of the sample, 3.0% to 7.6% reported at least one
non-fatal overdose during each 6-month study follow-up.
Multilevel modeling of data pertaining to the likelihood of non-fatal overdose showed that
there was significant between person variance. That is the estimate of participants
determined from the null models showed that the percentage of males and females who
experienced a non-fatal overdose was 5.8% and 5.7%, respectively. The 95% plausible value
ranges showed that the percentage of participants experiencing a non-fatal overdose during
follow-up varied between 3.6% to 9.1% among men and 3.6% to 8.8% among women.
Addition of the dummy variables for time (models 1) showed a significant decline in the
likelihood of non-fatal overdose especially among women. Among men (table 2), in
comparison to baseline, the likelihood of experiencing a non-fatal overdose declined at year
2 (OR=0.84, 95% CI=0.65, 1.07), year 3 (OR=0.79, 95% CI=0.61,1.02), and year 4
(OR=0.67, 95% CI=0.49,0.94) (significant linear trend, p=0.02). The decline was much
steeper among women (significant linear trend, p=0.01). In comparison to baseline, there
was a significant decreased likelihood of non-fatal overdose at year 1 (OR=0.64, 95%
CI=0.45, 0.93), year 2 (OR=0.58, 95% CI=0.42,0.80), year 3 (OR=0.45, 95% CI=0.42,0.80),
and year 4 (OR=0.32, 95% CI=0.20,0.50) (table 3).
Predictors were then tested as moderators of the intercept in the model in order to determine
if there were significant differences in likelihood of non-fatal overdose at baseline between
groups (e.g., between those born in Canada and those born outside of Canada) (model 3).
Among men (table 2), in comparison to those in the ARYS cohort, participants in the
VIDUS cohort were significantly less likely to experience non-fatal overdose (OR=0.60,
95% CI=0.42,0.87). Being homeless (OR=1.26, 95% CI=1.01, 1.58) and being on welfare
(OR=1.44,1.06,1.95) were associated with an increased likelihood of non-fatal overdose.
Education, sexual orientation, and birthplace were not significantly associated with non-fatal
overdose neither at baseline nor throughout follow-up. Of the drug injection behaviors,
cocaine (OR=2.54, 95% CI=1.93, 3.33) and speed injection (OR=1.50, 95% CI=1.18, 1.90)
were significantly associated with increased likelihood of non-fatal overdose in comparison
to those who did not inject cocaine or speed (table 2). Similarly, those who binged on
alcohol in the past 6 months (OR=1.69, 95% CI=1.33,2.17), in comparison to those who did
not, were significantly more likely to experience non-fatal overdose during follow-up.
Undergoing methadone treatment (OR=0.62, 95% CI=0.48,0.80) was significantly
associated with a decreased likelihood of non-fatal overdose (table 2).
Among women, those who were 20 years old or less (OR=2.68, 95%=1.14, 6.92)
homosexual (OR=1.59, 95% CI=1.12,2.25), completed high school (OR=1.49, 95%
CI=1.07,2.07), and on welfare (OR=1.71, 95% CI=1.20, 2.44) were significantly more likely
to experience non-fatal overdose during follow-up. Those who binged on alcohol (OR=1.59,
95% CI=1.11, 2.30), injected cocaine (OR=1.84, 95% CI=1.29,2.62) or morphine (OR=1.81,
95% CI=1.24,2.64) were more likely to experience a non-fatal overdose during follow-up.
Our objectives included determining whether depression was a predictor of increased
likelihood in non-fatal overdose and if social support was protective. The proportion of
participants who experienced a non-fatal overdose was higher among those with depressive
symptoms, in comparison to those without symptoms. For example, the estimated proportion
of men without and with depressive symptoms who experienced a non-fatal overdose was
4.3% and 7.7%, respectively. Similarly, among women, the estimated proportion without
and with depressive symptoms that experienced a non-fatal overdose were 4.2%, and 10.4%,
respectively. Among women only, in comparison to those with no social support,
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participants who had 3 or more sources of social support (OR=0.54, 95% CI=0.31, 0.93)
were significantly less likely to experience a non-fatal overdose at baseline and through
follow-up. However, having 1–2 sources of social support was not significantly associated
with non-fatal overdose. A depression X social support interaction term was tested and
found not to be significantly associated with non-fatal overdose at baseline or during follow-
up among men and women. These findings indicate that although depression is a predictor
for non-fatal overdose among men and women, social support is an independent predictor
among women as well. Also, a dose response of the effectiveness of social support might be
evident because more social support appeared to be indicative of greater protection from
non-fatal overdose.
4. DISCUSSION
In the current study, non-fatal overdose was common, with 3.0% to 7.6% reporting at least
one non-fatal overdose during each 6-month study follow-up. We found that among a cohort
of IDU in Vancouver, depression was a significant risk factor for non-fatal overdose. In
contrast, quantity of social support was protective against non-fatal overdose among women
only. These results demonstrate that participants who experience severe depressive
symptoms relative to their non-depressed counterparts are at greater risk of further health
consequences from their drug use. We found no statistical evidence of an interaction
between depression and social support, which indicates that social support is protective
among women who experienced depression and those who do not. However, the non-
significant finding may be due to lack of statistical power.
The findings that mental health status is an independent predictor of non-fatal overdose are
consistent with other work (Tobin and Latkin, 2003, Coffin et al., 2007). However, this
investigation is one of the first to use longitudinal analysis and thus demonstrates a
relationship between depression and non-fatal overdose over time. Individuals with poor
mental health status are more likely to use illicit drugs and therefore at greater risk for
overdose. Proposed interventions may include identifying people who are at risk of
developing depression or are clinically depressed and developing low-threshold (i.e., low
barrier or easy to access) and targeted interventions to help them better manage their
depressive symptoms.
One possible explanation for depression as a risk factor for non-fatal overdose is the
individual unintentionally overdoses. For example, individuals who are depressed are less
able to engage in self-maintenance behaviors (e.g., use adaptive emotion-regulation
strategies) that would facilitate their taking the precautions needed to avoid over-dosing
themselves (Aldao et al., 2010). Moreover, depression may reduce the ability to focus
attention whilst they are doing hazardous tasks (Aldao et al., 2010). More investigation is
needed to understand the direction of the association between depression and non-fatal
overdose across time.
We found a significant association between the number of sources of social support/
friendship and non-fatal overdose, among women only. These results might be due to
socialization differences stemming from expected social and occupational roles throughout
the life cycle (Flaherty and Richman, 1989). Researchers argue that women have been
socialized to develop a greater sensitivity to the needs of themselves and others, leading to a
greater dependence on social support and greater ability to provide social support (Flaherty
and Richman, 1989). As a result, social support was beneficial among women only. This has
important implications for the development and implementation of interventions designed to
prevent female IDU in experiencing overdose.
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Although a greater number of sources of social support was significantly associated with a
decreased risk for non-fatal overdose, previous research has indicated that more persons in
one’s support network is associated with increased risk for non-fatal overdose (Havens et al.,
2011, Latkin et al., 2004). This difference may be due to the way social support was
assessed. We asked participants to name different types of sources of social support.
However, the difference might also be driven by who participants identify as belonging to
their social network and the perceived quality of social support. For example, prior research
suggests that social connectedness can serve as a source of social pressure to encourage
positive or negative health behaviors that are considered normative within a social group
(Cohen, 2004, Umberson et al., 2010, Christakis and Fowler, 2008). Furthermore, perceived
adequacy or quality of social support is more strongly associated with mental health
outcomes than quantity of social support (Antonucci and Akiyama, 1987). Thus, it is
possible that in our sample, social support network members were more likely to encourage
positive health behaviors such as limited or controlled drug use, or participants were more
likely to perceive greater quality of social supports, unlike prior studies. Future research
should examine the specific characteristics and perceived adequacy of social support and
relationship with drug use.
These results also bolster support for interventions that reduce the adverse outcomes
associated with overdose, including supervised injection sites and take-home naloxone
distribution (Marshall et al., 2011, Center for Disease Control, 2012). While naloxone
programs are designed primarily to reduce the likelihood of a fatal overdose, previous
evaluations have suggested that supervised injection facilities may serve to reduce the risks
associated with non-fatal overdose (Kerr et al., 2007b). Further, health professionals, such as
nurses, can provide counseling on site, and provide resources within the community for help
to deal with depression and issues related to addiction.
This study has a number of limitations that should be noted. The ARYS, VIDUS, and
ACCESS cohorts are not random samples of the eligible population. As a result, findings
may not necessarily be generalizable to other urban areas in which drug use is common.
Information on all behaviors were collected by self-report, and therefore may be subject to
response biases. Also, it should be cautioned on the interpretation of “within-subject”
coefficients for repeated binary outcomes since most individuals never experience the event
during follow-up (Carlin et al., 2001). Lastly, our failure to detect an interaction between
depression and social support may reflect a problem related to statistical power.
In summary, we have demonstrated that among IDU, those who are depressed are more
likely to experience non-fatal overdose over time. Also, among women only, those who
have many sources of social support are less likely to experience non-fatal overdose.
Interventions may include helping those who are experiencing severe depressive symptoms
find adaptive ways to deal with mental health symptoms, including referral to low-threshold
community mental health programs. Provision of social support through counseling, health
professionals, and support groups might also help IDU prevent overdose.
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Table 1
Baseline characteristics of IDU participating in At Risk Youth Study (ARYS), Vancouver Injection Drug
Users Study (VIDUS II) and AIDS Care Cohort to Evaluate Access to Survival Services (ACCESS) cohorts in
Vancouver, British Columbia (n=1,931).
n %
Sex
 Female 653 33.8
 Male 1,278 66.2
Age
 ≤ 20 years 69 3.6
 > 20 years 1,862 96.4
Finished High School
 No 1,044 54.1
 Yes 887 45.9
Birthplace
 Canada 1,231 63.8
 Foreign-Born 700 36.3
Depressive Symptoms
 No 743 41.7
 Yes 1,040 58.3
Sexual Orientation
 Homosexual 281 14.6
 Heterosexual 1,650 85.5
Social Support
 None 406 21.0
 1–2 1,317 68.2
 3 or more 208 10.8
Homeless
 No 1,148 59.5
 Yes 783 40.6
Relationship status
 No 1,361 70.5
 Yes 570 29.5
Welfare
 No 264 13.7
 Yes 1,667 86.3
Jail in the last 6 months
 No 1,588 82.2
 Yes 343 17.8
Binge alcohol in the last 6 months
 No 1,419 73.5
 Yes 512 26.5
Heroin use in the last 6 months
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n %
 No 878 45.5
 Yes 1,053 54.5
Cocaine use in the last 6 months
 No 1,122 58.1
 Yes 809 41.9
Crystal Meth use in the last 6 months
 No 1,531 79.3
 Yes 400 20.7
Morphine use in the last 6 months
 No 1,564 81.0
 Yes 367 19.0
Speed use in the last 6 months
 No 1,633 84.6
 Yes 298 15.4
HIV Status
 Negative 1,321 69.1
 Positive 592 31.0
Help with injecting
 No 1487 77.0
 Yes 444 23.0
Methadone Treatment
 No 1,122 58.1
 Yes 809 41.9
Cohort
 ARYS 326 16.9
 ACCESS 578 29.9
 VIDUS 1,027 53.2
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